Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival

2015; Taylor & Francis; Volume: 33; Issue: 9 Linguagem: Inglês

10.3109/07357907.2015.1065499

1532-4192

Katia B Pagnano, Israel Bendit, Carla Boquimpani, Cármino Antônio De Souza, Eliana Cristina Martins Miranda, Ilana Zalcberg, Irene Larripa, Luciana Nardinelli, Rosana Antunes da Silveira, Laura Fogliatto, Nelson Spector, Vaneuza Araújo Moreira Funke, Ricardo Pasqüini, Vania Hungria, Carlos Chiattone, Nelma Clementino, Mônika Conchon, Elena Beatriz Moiraghi, José Luis García López, Carolina Pavlovsky, Miguel Arturo Pavlovsky, Eduardo Cervera, Luis Meillón, Belinda Pinto Simões, Nelson Hamerschlak, Alicia Helena Magarinos Bozzano, Ernesto Mayta, Jorge E. Cortés, Raquel Bengió,

Chronic Lymphocytic Leukemia Research

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.